

## Regular Article

## CLINICAL TRIALS AND OBSERVATIONS

## Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

Luca Ceriani,<sup>1</sup> Maurizio Martelli,<sup>2</sup> Pier Luigi Zinzani,<sup>3</sup> Andrés J. M. Ferreri,<sup>4</sup> Barbara Botto,<sup>5</sup> Caterina Stelitano,<sup>6</sup> Manuel Gotti,<sup>7</sup> Maria Giuseppina Cabras,<sup>8</sup> Luigi Rigacci,<sup>9</sup> Livio Gargantini,<sup>10</sup> Francesco Merli,<sup>11</sup> Graziella Pinotti,<sup>12</sup> Donato Mannina,<sup>13</sup> Stefano Luminari,<sup>14</sup> Anastasios Stathis,<sup>1</sup> Eleonora Russo,<sup>2</sup> Franco Cavalli,<sup>1</sup> Luca Giovannella,<sup>1</sup> Peter W. M. Johnson,<sup>15</sup> and Emanuele Zucca<sup>1</sup>

<sup>1</sup>Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; <sup>2</sup>Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy; <sup>3</sup>Institute of Hematology and Medical Oncology, Policlinico S. Orsola-Malpighi, Bologna, Italy; <sup>4</sup>Department of Oncology, Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy; <sup>5</sup>Hematology, Azienda Ospedaliera Città della Salute e della Scienza, Turin, Italy; <sup>6</sup>Hematology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy; <sup>7</sup>Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; <sup>8</sup>Hematology, Ospedale Businco, Cagliari, Italy; <sup>9</sup>Hematology, Policlinico Careggi, Florence, Italy; <sup>10</sup>Department of Hematology, Niguarda Ca' Granda Hospital, Milan, Italy; <sup>11</sup>Hematology Unit, Department of Oncology, Azienda Ospedaliera ASMN IRCCS Reggio Emilia, Italy; <sup>12</sup>Medical Oncology Unit, Ospedale di Circolo Fondazione Macchi, Varese, Italy; <sup>13</sup>Department of Hematology, Azienda Ospedaliera Papardo, Messina, Italy; <sup>14</sup>Oncology Hematology Department, Modena University, Modena, Italy; and <sup>15</sup>Cancer Research UK Centre, University of Southampton, Southampton, United Kingdom

## Key Points

- 18FDG PET/CT is a very important staging tool for patients with PMBCL.
- Metabolic activity defined by TLG on the baseline PET scan is a powerful predictor of PMBCL outcome.

The International Extranodal Lymphoma Study Group (IELSG) 26 study was designed to evaluate the role of <sup>18</sup>F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) in the management of primary mediastinal (thymic) large B-cell lymphoma (PMBCL). We examined the prognostic impact of functional PET parameters at diagnosis. Metabolic activity defined by the maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) was measured on baseline 18FDG PET/CT following a standard protocol in a prospectively enrolled cohort of 103 PMBCL patients. All received combination chemoimmunotherapy with doxorubicin- and rituximab-based regimens; 93 had consolidation radiotherapy. Cut-off values were determined using the receiver-operating characteristic curve. At a median

follow-up of 36 months, progression-free survival (PFS) and overall survival (OS) were 87% and 94%, respectively. In univariate analysis, elevated MTV and TLG were significantly associated with worse PFS and OS. Only TLG retained statistical significance for both OS ( $P = .001$ ) and PFS ( $P < .001$ ) in multivariate analysis. At 5 years, OS was 100% for patients with low TLG vs 80% for those with high TLG ( $P = .0001$ ), whereas PFS was 99% vs 64%, respectively ( $P < .0001$ ). TLG on baseline PET appeared to be a powerful predictor of PMBCL outcomes and warrants further validation as a biomarker. The IELSG 26 study was registered at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) as #NCT00944567. (*Blood*. 2015;126(8):950-956)

## Introduction

Primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is a distinct clinicopathological<sup>1-3</sup> and molecular<sup>4,5</sup> subtype of diffuse large B-cell lymphoma (DLBCL) arising from a small population of B cells within the thymus. It is characterized by a rapidly progressive anterior mediastinal mass, often with local invasion and compressive syndromes, and by recurrence at unusual extranodal sites.<sup>6</sup> PMBCL commonly affects young adults, and treatment with aggressive chemotherapy regimens and rituximab with or without radiotherapy appears to yield better outcomes than in other DLBCLs, partly as a result of the younger age and earlier stage at presentation, with 5-year survival rates of over 90% in recent studies.<sup>7,8</sup>

However, salvage treatment of the few patients failed by initial therapy has a poor outcome, as a result of rapidly emerging chemorefractory

disease, often around the completion of the first course of treatment.<sup>9,10</sup> If it were possible to predict this important minority, it would allow for the development of risk-stratified approaches such as early intensification with infusional regimens or even elective myeloablative therapy.

Hence, there is a need for reliable prognostic markers. The International Prognostic Index (IPI), the conventional tool used to predict outcome for DLBCL, has limited utility in PMBCL because of the young patient age and the usual confinement of the disease to the mediastinum.<sup>11</sup> This is reflected in the observation that most patients have low-risk IPI scores at presentation.<sup>8,12</sup>

<sup>18</sup>F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) is increasingly used to monitor

Submitted December 30, 2014; accepted May 24, 2015. Prepublished online as *Blood* First Edition paper, June 18, 2015; DOI 10.1182/blood-2014-12-616474.

L.C. and M.M. contributed equally to this study.

P.W.M.J. and E.Z. contributed equally to this study.

The online version of this article contains a data supplement.

There is an Inside *Blood* Commentary on this article in this issue.

Presented in part at the 12th International Conference on Malignant Lymphoma, Lugano, Switzerland, June 19-20, 2013.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2015 by The American Society of Hematology

treatment response and guide clinical decisions on treatment strategies for FDG-avid lymphomas, including PMBCL.<sup>13-15</sup> We have previously shown<sup>8</sup> that liver FDG uptake was the optimal cutoff value to predict outcome, providing a validation of the utility for a 5-point scale (Deauville criteria, initially developed for the interim PET evaluation of Hodgkin disease and DLBCL)<sup>16</sup> in end-of-therapy PET evaluation of PMBCL.

The objective of the present study was to investigate whether the main quantitative baseline PET-derived metabolic parameters can predict prognosis, and to compare these parameters with the commonly used clinical indices, in patients with PMBCL.

## Patients and methods

### Patient population

Between January 2007 and July 2010, 125 patients with histologically proven PMBCL were prospectively enrolled in the International Extranodal Lymphoma Study Group (IELSG) 26 study (<http://clinicaltrials.gov/ct2/show/NCT00944567>) and treated with the R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-CHOP-like R-VACOP-B (rituximab plus etoposide, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin) or R-MACOP-B (rituximab plus methotrexate, leucovorin, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin) regimens according to local policy. Consolidation with mediastinal involved field radiotherapy as indicated by local guidelines was allowed; all patients treated received, within 8 weeks of the last dose of chemotherapy, a dose of at least 30 Gy on the original tumor volume. Treatment details have been reported previously.<sup>8</sup> The study was conducted in accordance with the precepts of the Helsinki declaration and received approval from the local research ethical committee of each participating center.

### 18FDG-PET imaging procedures

The study protocol included mandatory technical procedures for the acquisition and elaboration of PET imaging, based on the state of the art at the time when the study was planned.<sup>17</sup> Baseline PET scans were performed within 14 days before the first chemotherapy. In cases where urgent treatment was required and the PET scan could not be performed before therapy started, the baseline scan was omitted after discussion with the clinical coordinators; these cases were excluded from this analysis. PET/CT imaging was performed on full-ring integrated PET/CT systems. Each center was required to follow an active quality-control and quality-assessment protocol.<sup>17</sup> PET and CT images were acquired in the same session. CT scans obtained with a low-dose protocol were used for attenuation-correction of the PET images. All patients were fasting for at least 6 hours before the injection of 250 to 370 MBq (4.5 MBq/kg) 18FDG. Blood glucose measured before injection of the radiotracer was <160 mg/dL in all patients. PET data were acquired in 2- or 3-dimensional mode from the midthigh toward the base of the skull after a standardized uptake time of 60 minutes ( $\pm 5$  minutes). The PET acquisition time was at least 3 minutes per bed position. Images were reconstructed with validated and commercially available iterative algorithms, and standardized uptake values (SUV) were automatically calculated. All PET/CT image data were stored in Digital Imaging and Communications in Medicine format and sent to the core laboratory for central review. The adherence to the technical protocol requirements was centrally controlled for each data set. A central blind analysis was performed by one trained nuclear physician (L.C.) without information on the clinical outcome.

### 18FDG PET parameters

The 18FDG-PET/CT images were obtained at baseline for initial staging in 103 out of 125 patients and analyzed following a standard protocol on a dedicated workstation (Siemens Syngo MMWP Workstation VE36A; Siemens, Erlangen, Germany). Dedicated software (Syngo TrueD) automatically estimated the average and maximum SUV (SUVmean and SUVmax) and metabolic tumor volume (MTV) of the entire mediastinal lesion using an isocontour threshold method based on 25% of the SUVmax. In 8 cases, the boundaries of the lesion

**Table 1. Patient clinical characteristics at presentation**

Characteristic (n = 103 unless otherwise specified)	No. (%) of patients
<b>Age</b>	
Median (interquartile range), y	33 (26-41)
≤60 y	97 (94)
<b>Female sex</b>	63 (61)
<b>Performance status</b>	
ECOG 0-1	88 (85)
ECOG >1	15 (15)
B-symptoms at presentation	38 (37)
<b>Bulky disease</b>	
Max mediastinal lesion >7 cm	89 (86)
Max mediastinal lesion >10 cm	54 (52)
Extramediastinal involvement ≥1 site	14 (14)
Bone marrow involvement	2 (2)
<b>Ann Arbor stage</b>	
I-II	97 (94)
III-IV	6 (6)
LDH >normal upper value*	77 (75)
<b>IPI</b>	
Low and low-intermediate risk	99 (96)
Intermediate-high and high risk	4 (4)
<b>aaIPI (n = 97)</b>	
Low and low-intermediate risk	82 (85)
Intermediate-high and high risk	15 (15)
<b>Front-line treatment</b>	
R-CHOP or R-CHOP like regimen*	16 (16)
R-VACOP-B or R-MACOP-B regimen*	87 (84)
RT	93 (90)

RT, consolidation mediastinal radiotherapy.

\*Details on the immunochemotherapy regimens and radiotherapy plans have been previously reported.<sup>8</sup>

estimated automatically were partly manually redrawn to exclude physiological cardiac activity. The total lesion glycolysis (TLG) was then calculated as the product of SUVmean and MTV.<sup>18</sup>

After an experimental evaluation of different threshold levels (20%, 25%, 30%, 35%, 41%, and 50% of the SUVmax) carried out on a subgroup of 20 cases, 25% of the SUVmax was identified as the best cutoff value. The choice of the threshold was based on visual comparative analysis performed by 2 independent observers (L.C. and L.G.), taking into account the best fit between “metabolic edges” and anatomical boundaries, in particular at the interface between tumor lesion and lung tissue, which is the most clearly identifiable on the CT low-dose images. The presence of extramediastinal disease (found in 14/103 baseline PET scans) contributed significantly to the MTV in only 1 patient (29% of the total volume), whereas in all the others, the lesions were very small (usually single FDG-positive distant lymph nodes), involving <5% of the MTV value. This methodology showed very high interobserver reproducibility (Pearson correlation coefficient >0.99 and  $P < .0001$ ) for the calculation of all quantitative parameters.

### Statistical methods

The PET-associated functional parameters were analyzed as both continuous and dichotomized variables, using receiver-operating characteristic (ROC) analysis to identify the optimal cutoff point. Overall survival (OS) and progression-free survival (PFS) were defined according to the revised National Cancer Institute criteria<sup>13</sup> and estimated using the Kaplan-Meier or life-table method as appropriate. Follow-up was calculated as the median time to censoring using a reverse Kaplan-Meier analysis.<sup>19</sup> Differences between survival curves associated with discrete or dichotomized variables were analyzed using the log-rank test. Cox regression was used to estimate the hazard ratio (HR) and its confidence interval (CI). The exact 95% CIs were calculated for incidence percentages.  $P$  values of  $\leq .05$  (2-sided test) were considered to indicate statistical significance. Statistical analysis was conducted using the STATA 11 software package (Stata Corp, College Station, TX).

Table 2. Baseline 18FDG-PET parameters

Parameter	Median	Interquartile range	ROC curve for PFS					ROC curve for OS				
			AUC (95% CI)	P	Cutoff	Sensitivity (95% CI)	Specificity (95% CI)	AUC (95% CI)	P	Cutoff	Sensitivity (95% CI)	Specificity (95% CI)
SUVmax	18.8	15.5-23	0.647 (0.476-0.819)	.09	22.2	61.5% (31.6-86.1)	75.6% (65.4-84.0)	0.711 (0.488-0.935)	.06	22.2	83.3% (35.9-99.6)	74.2% (64.3-92.6)
MTV	406	267-641	0.814 (0.681-0.946)	.0001	703	69% (38.6-90.9)	87.8% (79.2-93.7)	0.812 (0.661-0.941)	.0001	490	100% (54.1-100)	60.8% (50.4-70.6)
TLG	4261	2363-6398	0.867 (0.746-1.0)	.0001	5814	92.1% (64.0-99.8)	77.7% (66.6-84.9)	0.921 (0.841-1.0)	.0001	6031	100% (54.1-100)	74.2% (64.3-82.6)

## Results

Detailed clinical features and outcome of the patients enrolled in the IELSG 26 study have been published previously.<sup>8</sup> Baseline PET/CT studies were available in 103 out of 125 patients, having been omitted in 20 patients because of the urgency of treatment and excluded in 2 cases (after central control) on technical grounds due to unacceptable lengthening of the uptake time. Table 1 summarizes the demographic and clinical characteristics of the 103 patients included in the present analysis. All had initial treatment with rituximab- and anthracycline-containing regimens, and 93 also had consolidation radiotherapy to the mediastinum. At a median follow-up of 36 months (interquartile range, 31-45 months), 13 patients had disease progression or relapse and 6 had died. The estimated 5-year PFS and OS rates were 87% (95% CI, 79%-92%) and 94% (95% CI, 87%-97%), respectively.

The description of the baseline functional PET parameters studied, SUVmax, MTV, and TLG is depicted in Table 2, which summarizes the results of the ROC analysis used to identify optimal cutoff points.

In univariate analysis of the PET parameters as continuous variables (Cox regression), a significantly higher risk of progression was associated with an increase in MTV (HR, 1.36; 95% CI, 1.16-1.61 for any increment of  $10^2$  mL;  $P < .001$ ) and TLG (HR, 1.40; 95% CI, 1.25-1.58 for any increment of  $10^3$  mL;  $P < .001$ ), but not with an increase in SUVmax (HR, 1.08; 95% CI, 0.98-1.18 for any increment of 1 unit;  $P = .119$ ). OS also appeared to be significantly correlated with an increase in either MTV (HR, 1.39 for each increment of  $10^2$  mL; 95% CI, 1.08-1.77;  $P = .009$ ) or TLG (HR, 1.47 for each 103-unit increment; 95% CI, 1.22-1.76;  $P < .001$ ), but not SUVmax (HR, 1.11; 95% CI, 0.97-1.27 for any increment of 1 unit,  $P = .117$ ).


Univariate analysis of dichotomized parameters (log-rank test) showed a statistically significant association of high SUVmax, MTV, and TLG with worse PFS and OS (Figure 1). Elevated TLG and MTV were more frequently seen in patients with bulk  $>10$  cm (supplemental Table 1, available on the *Blood* Web site). Among the clinical features at presentation, bulk  $>10$  cm was also associated with shorter PFS, but not OS (Table 3), whereas no impact on outcome was seen in this study population for gender, age, performance status, B-symptoms, serum lactate dehydrogenase (LDH), stage, IPI, and age-adjusted IPI (aaIPI) (supplemental Table 2). Nevertheless, on multivariate analysis (Table 4), only TLG retained statistical significance for both OS and PFS controlling for MTV (Cox models for either PFS or OS) and tumor bulk (included only in the Cox model for PFS).

Long-term outcome was significantly better for patients with low TLG (below the cutoff value) compared with those with high TLG (above the cutoff value), with 5-year OS of 100% vs 80% and 5-year PFS of 99% vs 64%, respectively (Figure 1).

Despite limited statistical power, baseline TLG remained the strongest predictor of outcome for the 82 patients with stage I or II disease in univariate analysis of OS (log-rank test,  $P = .0027$ ) and PFS (log-rank test,  $P = .0001$ ), as well as in Cox models controlling for MTV (HR, 4.21 with  $P = .018$  for OS; HR, 1.70 with  $P = .009$  for PFS).

## Discussion

There is increasing evidence of the prognostic value of quantitative parameters obtained from initial staging by 18FDG-PET/CT in patients with high-grade non-Hodgkin lymphoma, in addition to the standard qualitative visual analysis.<sup>15,20,21</sup> Initially, SUV was the most widely studied parameter.<sup>22-24</sup> More recently, growing recognition of



**Figure 1.** Estimates of OS and PFS according to the value of functional 18FDG-PET parameters in the PET/CT scan performed during the initial staging of 103 patients with primary mediastinal large cell lymphoma enrolled in the IELSG 26 prospective study. (A-C) Kaplan-Meier estimates of OS. (D-F) Kaplan-Meier estimates of PFS. Cutoff values are reported in Table 2. High, above the cutoff values calculated by ROC analysis; low, at or below the cutoff values calculated by ROC analysis.

volume-based metabolic assessment has emerged, including MTV and TLG as promising prognostic indices in solid tumors,<sup>25</sup> multiple myeloma,<sup>26</sup> and malignant lymphomas.<sup>27-30</sup> Among these functional parameters, TLG appears of particular interest as a prognostic pointer in DLBCL.<sup>27,31-35</sup> However, no specific study has so far addressed PMBCL as a distinct subtype<sup>2-6</sup> in which the metabolic response rate appears clearly inferior to that seen in other DLBCLs and Hodgkin lymphoma.<sup>7,8,36</sup>

Although the overall results of treatment of PMBCL are favorable,<sup>7,8</sup> there remains a clear minority in whom the initial treatment fails,

following which second-line treatment is frequently unsuccessful.<sup>9,10</sup>

In a retrospective series from the Princess Margaret Hospital in Toronto, the overall response rate to salvage chemotherapy (25% vs 48%) and 2-year OS after progression or relapse (15% vs 34%) were significantly inferior in 37 patients with relapsing or refractory PMLCL compared with a control group of 143 relapsing patients with other DLBCLs.<sup>9</sup> In a retrospective Italian series, 138 consecutive patients were treated with the same chemotherapy combinations used in this study (CHOP or MACOP-B/VACOP-B) but without rituximab.



**Table 3. Univariate analysis (life tables and log-rank test) of the difference between OS and PFS according to dichotomized baseline PET parameters and the presence of a bulky lesion**

Parameter	5-y OS (95% CI)	P	5-y PFS (95% CI)	P
<b>SUVmax</b>		.0025		.0065
Low	99% (91%-99.8%)		93% (84%-97%)	
High	83% (64%-93%)		73% (54%-86%)	
<b>MTV</b>		.0036		<.0001
Low	100% (n.a.)		95% (88%-98%)	
High	86% (72%-94%)		55% (31%-73%)	
<b>TLG</b>		.0001		<.0001
Low	100% (n.a.)		99% (90%-99.8%)	
High	80% (62%-91%)		64% (45%-77%)	
<b>Bulky disease</b>		.120		.013
<10 cm	98% (86%-99%)		96% (85%-99%)	
≥10 cm	91% (79%-96%)		80% (66%-88%)	

The presence of a bulky lesion was statistically significant only for PFS. All the remaining baseline clinical parameters, namely, gender, age, performance status, B-symptoms, LDH, stage, and the international prognostic indices, had no statistically significant impact on both OS and PFS and are not included in this table but are reported in the online appendices. Cutoff values used for the dichotomization of functional PET parameters (SUVmax, MTV, TLG) are reported in Table 2.

Seventy-five percent of patients in complete remission received consolidation radiotherapy. Event-free survival and OS for patients treated with MACOP-B/VACOP-B were significantly better, but all the patients with stable disease or progression during chemotherapy (26) and all those relapsing after initial remission (12) died of lymphoma, irrespective of first-line and subsequent treatment type.<sup>10</sup> In contrast to this finding, other studies have reported good outcomes in small groups of patients with chemosensitive relapse treated with high-dose therapy and autologous stem cell rescue.<sup>9,37</sup> They showed that chemotherapy responsiveness immediately before transplantation is the strongest survival predictor. All these results highlight the need for studies focused on identifying poor-risk PMBCL patients to test novel induction and salvage strategies in advance of overt treatment failure.

Most patients with PMBCL present before the age of 60 years with early symptoms due to bulky mediastinal lesions that infiltrate the adjacent thoracic structures. For this reason, they rarely have other adverse prognostic factors.<sup>6</sup> The IPI was originally developed for DLBCL, and studies of its utility in PMBCL have been contradictory.<sup>10,38-40</sup> This may in part reflect differences in assigning stage when contiguous extranodal sites are involved.<sup>41</sup> Moreover, the fact that most patients have elevated LDH reduces the usefulness of its discriminatory power and further affects the utility of IPI and aaIPI.<sup>38</sup>

As confirmed in the current series, conventional clinical prognostic indices for DLBCL, such as IPI and aaIPI, have only limited utility of identifying those who may benefit from different treatment strategies.<sup>8,12</sup>

We showed that TLG, which represents a combined assessment of tumor volume and metabolism on baseline 18FDG-PET/CT, was the most robust predictor of outcome not only as a dichotomized variable but also as a continuous parameter, irrespective of the cutoff point. The negative predictive power is extremely high, as there were no deaths and only 1 relapse among the patients with low TLG at diagnosis.

Our study was conducted in a large number of uniformly treated PMBCL patients. A small pilot study of 20 patients with DLBCL from the Massachusetts General Hospital also suggested that high baseline TLG may identify patients who are at increased risk of relapse after conventional R-CHOP<sup>34</sup>. A survey from South Korea of 140 patients with DLBCL treated with R-CHOP showed that TLG is a better predictor of outcome than the IPI.<sup>27</sup> Our study represents the largest prospectively collected series of PMBCL investigated with a central review of PET scans in which the quantitative functional parameters

were retrospectively analyzed. The PET imaging was obtained following a strictly defined technical procedure, although detailed cross-calibration for equipment at the different centers was not possible. This may represent a limitation for a study focused on quantitative variables; however, our results are in keeping with the findings of the other studies from the United States and Korea and seem particularly promising for the early prediction of treatment failure in PMBCL.

The use of TLG in routine clinical practice would be premature, as there is a lack of a standardized methodology for the estimation of MTV and the TLG derived from this. Different methods and a wide range of threshold levels have been proposed to calculate the volume-based PET parameters either in solid tumors or in different subtypes of lymphoma (mainly DLBCL).<sup>25-35,42-45</sup> Moreover, there are no published technical references about the methodology for the calculation of the volume-based PET parameters and definition of specific cutoff values in PMBCL.

Taking into account these points and the features of this disease, which is characterized by its thymic origin and presentation with a bulky FDG-avid mediastinal mass, we elected to experimentally define the PMBCL-specific volumetric PET parameters.

We estimated the MTV of PMBCL using an isocontour threshold method based on 25% of the SUVmax, which is lower than the 41% proposed by Boellard et al<sup>46</sup> for the evaluation of tumoral lesions and tested by Meignan et al in Hodgkin lymphoma and DLBCL.<sup>44</sup> However, our choice of a 25% threshold is justified by the very high FDG uptake currently found in the large and usually single PMBCL presenting mass (in our population, the median SUVmax was 18.8, with an interquartile range of 15.5 to 23) and is in keeping with other reports demonstrating that the ideal threshold (ie, the one that most accurately reflects the pathological tumor size) is inversely proportional to the lesion SUVmax.<sup>43,45</sup> In this relationship, the best threshold is between 30% and 20% when SUVmax is between 20 and 30,<sup>45</sup> and our results are in line with these findings.

We are aware that the use of a relatively low cutoff value may result in MTV overestimation in patients with small masses and reduced metabolic activity; however, this risk does not apply to this study population, where >85% of patients had a maximum tumor diameter >7 cm and only 4 patients had a SUVmax <11. Moreover, to mitigate potential bias, TLG was homogeneously estimated in all patients during the central review of PET scans.

Hence, the effectiveness of TLG to risk stratify patients and the possibility of further improving the positive predictive value by combining TLG with other clinical and imaging parameters may warrant further studies. Indeed, this easily and early accessible parameter can help identify the few PMBCL patients who will eventually relapse and may be useful for designing trials aimed at

**Table 4. Multivariate analysis (Cox proportional hazard models for either OS or PFS)**

Parameter	HR	95% CI	P
<b>Multivariate analysis of OS</b>			
<b>(103 subjects, 6 deaths)</b>			
MTV (increments of 10 <sup>2</sup> ml)	0.96	0.66-1.40	.833
TLG (increments of 10 <sup>3</sup> )	1.49	1.18-1.89	.001
<b>Multivariate analysis of PFS</b>			
<b>(103 subjects, 13 events)</b>			
Bulky disease (<10 cm vs ≥10 cm)	1.73	0.31-9.52	.526
MTV (increments of 10 <sup>2</sup> mL)	1.03	0.80-1.33	.812
TLG (increments of 10 <sup>3</sup> mL)	1.36	1.16-1.58	<.001

Each as a whole was statistically significant, and in both models, TLG resulted in a significantly longer survival time after controlling for mediastinal bulk and MTV in PFS and for MTV in OS.

improving their poor prognosis. In this setting, TLG may be a tool to select patients to be considered for elective front-line consolidation with myeloablative therapies. An alternative strategy for this group might be to use the dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (DA-EPOCH-R) regimen, which has demonstrated very promising results<sup>7</sup> but may not be necessary for the large proportion of patients who are probably curable with R-CHOP or R-MACOP-B/R-VACOP-B alone.<sup>8</sup> Even if PET restaging at the end of chemotherapy can be used to reassess the risk of progression,<sup>8</sup> a reliable baseline prognostic marker might allow us to determine who needs more complex infusional therapy and who is just as likely to be cured with the conventional regimens.

## Acknowledgments

A list of centers and investigators participating to the IELSG 26 study is reported in the online Appendix.

The authors thank Rita Gianasio Gianocca for her editorial assistance, the nursing and medical staff who looked after the patients at each center, and Dr Cassio P. De Campos for his critical reading of the manuscript and valuable review of the statistical analysis.

The study was endorsed by the Italian Lymphoma Foundation and by Cancer Research United Kingdom. We are grateful for the valuable contributions of Elena Porro, Monica Bellei, Marina Cesaretti, Kelly Cozens, and Carol J. Tyas to study coordination and data management. This study has been supported by grants ICP OCS-01709-04-2005 and ICP OCS-02062-03-2007 from Oncosuisse.

## Authorship

L.C., E.Z., M.M., and P.W.M.J. designed the research and supervised the study; L.C., L.G., E.Z., M.M., P.W.M.J., and A.J.M.F. analyzed and interpreted data and wrote the manuscript; and all authors provided study materials or patients, contributed to the collection and assembly of data, discussed the results, critically reviewed the manuscript, and had final responsibility for the decision to submit.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Emanuele Zucca, IELSG Operation Office, Ospedale San Giovanni, CH-6500 Bellinzona, Switzerland; e-mail: [ielsg@ticino.com](mailto:ielsg@ticino.com).

## References

- Boleti E, Johnson PW. Primary mediastinal B-cell lymphoma. *Hematol Oncol*. 2007;25(4):157-163.
- Gaulard P, Harris NL, Pileri SA, et al. Primary mediastinal (thymic) large B-cell lymphoma. In: Swerdlow S, Campo E, Harris NL, et al., eds. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon: IARC; 2008:250-253.
- Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. *Blood*. 2011;118(10):2659-2669.
- Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. *Blood*. 2003;102(12):3871-3879.
- Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. *J Exp Med*. 2003;198(6):851-862.
- Johnson PW, Davies AJ. Primary mediastinal B-cell lymphoma. *Hematology Am Soc Hematol Educ Program*. 2008;349-358.
- Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. *N Engl J Med*. 2013;368(15):1408-1416.
- Martelli M, Ceriani L, Zucca E, et al. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. *J Clin Oncol*. 2014;32(17):1769-1775.
- Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2008;49(7):1329-1336.
- Todeschini G, Secchi S, Morra E, et al. Primary mediastinal large B-cell lymphoma (PMBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. *Br J Cancer*. 2004;90(2):372-376.
- A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. *N Engl J Med*. 1993;329(14):987-994.
- Abou-Elella AA, Weisenburger DD, Vose JM, et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. *J Clin Oncol*. 1999;17(3):784-790.
- Cheson BD, Pfistner B, Juweid ME, et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. *J Clin Oncol*. 2007;25(5):579-586.
- Moskowitz CH. Interim PET-CT in the management of diffuse large B-cell lymphoma. *Hematology Am Soc Hematol Educ Program*. 2012;2012:397-401.
- Cheson BD. Role of functional imaging in the management of lymphoma. *J Clin Oncol*. 2011;29(14):1844-1854.
- Altman DG, Bland JM. Diagnostic tests 2: Predictive values. *BMJ*. 1994;309(6947):102.
- Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. *J Nucl Med*. 2006;47(5):885-895.
- Larson SM, Erdi Y, Akhurst T, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. *Clin Positron Imaging*. 1999;2(3):159-171.
- Altman DG, De Stavola BL, Love SB, Stepniowska KA. Review of survival analyses published in cancer journals. *Br J Cancer*. 1995;72(2):511-518.
- Juweid ME, Stroobants S, Hoekstra OS, et al; Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. *J Clin Oncol*. 2007;25(5):571-578.
- Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. *Leuk Lymphoma*. 2009;50(8):1257-1260.
- Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. *J Nucl Med*. 2009;50(4):527-533.
- Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al; Groupe d'étude des lymphomes de l'adulte (GELA). SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. *Blood*. 2011;118(1):37-43.
- Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and  $\Delta$ SUVmax. *Eur J Nucl Med Mol Imaging*. 2013;40(9):1312-1320.
- Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. *Eur J Nucl Med Mol Imaging*. 2013;40(2):290-301.
- Fonti R, Larobina M, Del Vecchio S, et al. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma. *J Nucl Med*. 2012;53(12):1829-1835.
- Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. *Cancer*. 2013;119(6):1195-1202.
- Song MK, Chung JS, Shin HJ, et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell

- lymphoma without extranodal site involvement. *Ann Hematol*. 2012;91(5):697-703.
29. Song MK, Chung JS, Shin HJ, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. *Cancer Sci*. 2012;103(3):477-482.
  30. Yang DH, Ahn JS, Byun BH, et al. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. *Ann Hematol*. 2013;92(4):471-479.
  31. Manohar K, Mittal BR, Bhattacharya A, Malhotra P, Varma S. Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin's lymphoma. *Nucl Med Commun*. 2012;33(9):974-981.
  32. Gallicchio R, Mansueto G, Simeon V, et al. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. *Eur J Haematol*. 2014;92(5):382-389.
  33. Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on <sup>18</sup>F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. *Eur J Nucl Med Mol Imaging*. 2013;40(9):1321-1329.
  34. Esfahani SA, Heidari P, Halpern EF, Hochberg EP, Palmer EL, Mahmood U. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. *Am J Nucl Med Mol Imaging*. 2013;3(3):272-281.
  35. Cazaentre T, Morschhauser F, Vermandel M, et al. Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma. *Eur J Nucl Med Mol Imaging*. 2010;37(3):494-504.
  36. Savage KJ, Yenson PR, Shenkier T, et al. The outcome of primary mediastinal large B-cell lymphoma (PMBCL) in the R-CHOP treatment era [abstract]. *Blood*. 2012;120(21):303.
  37. Sehn LH, Antin JH, Shulman LN, et al. Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation. *Blood*. 1998;91(2):717-723.
  38. Hamlin PA, Portlock CS, Straus DJ, et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. *Br J Haematol*. 2005;130(5):691-699.
  39. Zinzani PL, Martelli M, Bertini M, et al; International Extranodal Lymphoma Study Group (IELSG). Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. *Haematologica*. 2002;87(12):1258-1264.
  40. Savage KJ, Al-Rajhi N, Voss N, et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. *Ann Oncol*. 2006;17(1):123-130.
  41. Savage KJ. Primary mediastinal large B-cell lymphoma. *Oncologist*. 2006;11(5):488-495.
  42. Freudenberger LS, Antoch G, Schütt P, et al. FDG-PET/CT in re-staging of patients with lymphoma. *Eur J Nucl Med Mol Imaging*. 2004;31(3):325-329.
  43. Zhong X, Yu J, Zhang B, et al. Using 18F-fluorodeoxyglucose positron emission tomography to estimate the length of gross tumor in patients with squamous cell carcinoma of the esophagus. *Int J Radiat Oncol Biol Phys*. 2009;73(1):136-141.
  44. Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. *Eur J Nucl Med Mol Imaging*. 2014;41(6):1113-1122.
  45. Hyun SH, Choi JY, Shim YM, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. *Ann Surg Oncol*. 2010;17(1):115-122.
  46. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. *Eur J Nucl Med Mol Imaging*. 2015;42(2):328-354.



2015 126: 950-956  
doi:10.1182/blood-2014-12-616474 originally published  
online June 18, 2015

## **Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma**

Luca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, Andrés J. M. Ferreri, Barbara Botto, Caterina Stelitano, Manuel Gotti, Maria Giuseppina Cabras, Luigi Rigacci, Livio Gargantini, Francesco Merli, Graziella Pinotti, Donato Mannina, Stefano Luminari, Anastasios Stathis, Eleonora Russo, Franco Cavalli, Luca Giovannella, Peter W. M. Johnson and Emanuele Zucca

---

Updated information and services can be found at:

<http://www.bloodjournal.org/content/126/8/950.full.html>

Articles on similar topics can be found in the following Blood collections

[Clinical Trials and Observations](#) (4660 articles)

[Free Research Articles](#) (4779 articles)

[Lymphoid Neoplasia](#) (2664 articles)

---

Information about reproducing this article in parts or in its entirety may be found online at:

[http://www.bloodjournal.org/site/misc/rights.xhtml#repub\\_requests](http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests)

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>